Red blood cell transfusion risks in patients with end-stage renal disease.
Prior to the introduction of recombinant human erythropoietin (EPO), red blood cell (RBC) transfusions were frequently required when iron and anabolic steroids failed to improve the clinical symptoms of anemia associated with hemoglobin (Hb) levels that were commonly less than 7 g/dl. After the approval of EPO in the United States in 1989, the Hb levels of patients on hemodialysis dramatically improved and the need for RBC transfusions decreased significantly. The need for RBC transfusion remains for patients who require an immediate increase in their RBC mass due to symptomatic anemia and is likely to increase due to changes in the management of anemia in dialysis patients resulting from clinical trials data, regulatory changes, and new reimbursement policies for EPO. The safety of the blood supply has greatly improved over the last few decades, and the risk of transfusion-transmitted diseases has now been dramatically reduced. Noninfectious complications of transfusion currently cause the majority of morbidity and mortality associated with transfusion in the United States. Transfusion also brings a risk of alloimmunization, a particular concern for dialysis patients waiting for kidney transplantation. Knowledge of the risks of RBC transfusions will help clinicians better assess the risks and benefits of transfusing patients with ESRD. This article reviews the modern day infectious and noninfectious risks of allogeneic RBC transfusions.
Division of Laboratory Medicine, Department of Pathology, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Yvette C
YC
Tanhehco
Jeffrey S
JS
Berns
D000740:Anemia / Q000209:etiology* / Q000628:therapy*; D017848:Blood-Borne Pathogens; D017707:Erythrocyte Transfusion / Q000009:adverse effects*; D004921:Erythropoietin / Q000494:pharmacology; D006397:Hematinics / Q000494:pharmacology; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D006435:Renal Dialysis / Q000009:adverse effects
D006397:Hematinics; D006454:Hemoglobins; D004921:Erythropoietin